Form 8-K - Current report:
SEC Accession No. 0001213900-25-032176
Filing Date
2025-04-15
Accepted
2025-04-15 17:05:54
Documents
14
Period of Report
2025-04-11
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0238443-8k_apimeds.htm   iXBRL 8-K 23529
2 AMENDED AND RESTATED BYLAWS OF APIMEDS PHARMACEUTICALS US, INC. ea023844301ex3-1_apimeds.htm EX-3.1 141934
  Complete submission text file 0001213900-25-032176.txt   370011

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cik0001894525-20250411.xsd EX-101.SCH 3044
4 XBRL LABEL FILE cik0001894525-20250411_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE cik0001894525-20250411_pre.xml EX-101.PRE 22369
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0238443-8k_apimeds_htm.xml XML 3488
Mailing Address 2 EAST BROAD STREET 2ND FLOOR HOPEWELL NJ 08525
Business Address 2 EAST BROAD STREET 2ND FLOOR HOPEWELL NJ 08525 609-751-4485
Apimeds Pharmaceuticals US, Inc. (Filer) CIK: 0001894525 (see all company filings)

EIN.: 851099700 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42545 | Film No.: 25840394
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)